Study S001686

A Phase 2, Randomized, Open-Label, Controlled Trial to Evaluate the Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07521631
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 372
Start: 2026-03-31
Primary completion: 2027-02-04
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Obesity
Interventions: DRUG:HDM1005 dose level 1; DRUG:HDM1005 dose level 2; DRUG:HDM1005 dose level 3; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Primary Outcome [week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.